Construction, optimization and testing of african Trypanosomiasis DNA vaccine prototypes with improved nuclease resistance by Magalhães, Salomé Alexandra de Sá
 UNIVERSIDADE DE LISBOA 
FACULDADE DE CIÊNCIAS 
DEPARTAMENTO DE BIOLOGIA VEGETAL 
 
 
 
 
Construction, optimization and testing of African 
Trypanosomiasis DNA vaccine prototypes with 
improved nuclease resistance  
 
 
 
Salomé Alexandra de Sá Magalhães 
 
 
 
MESTRADO EM BIOLOGIA MOLECULAR HUMANA 
 
 
 
DISSERTAÇÃO ORIENTADA PELOS PROFESSORES DOUTORES: 
 
DUARTE MIGUEL DE FRANÇA TEIXEIRA DOS PRAZERES – INSTITUTO SUPERIOR 
TÉCNICO DA UNIVERSIDADE TÉCNICA DE LISBOA 
 
MARIA DO CÉU CORREIA – FACULDADE DE CIÊNCIAS DA UNIVERSIDADE DE LISBOA 
 
 
 
LISBOA 2008 
 i 
Index 
 
Tables ......................................................................................................................................... v 
Abstract...................................................................................................................................... vi 
Resumo..................................................................................................................................... vii 
1. Introduction..................................................................................................................... - 1 - 
1.1. Human African Trypanosomiasis ............................................................................ - 1 - 
1.2. Immunologic system and interaction with Trypanosomes........................................ - 3 - 
1.3. Vaccine types ......................................................................................................... - 4 - 
2. Work aims ...................................................................................................................... - 7 - 
3. Materials and Methods ................................................................................................... - 7 - 
3.1. Construction of DNA vaccine prototypes with increased nuclease resistance ......... - 7 - 
3.1.1. Plasmid construction ....................................................................................... - 7 - 
3.1.2. Bacterial transformation .................................................................................. - 8 - 
3.2. In vitro testing ......................................................................................................... - 9 - 
3.2.1. Mammalian cell culture and Transfection ........................................................ - 9 - 
3.2.2. Assessment of fluorescent protein expression by Flow Cytometry analysis and 
Fluorescence Microscopy ............................................................................................... - 9 - 
3.2.3. Determination of number of plasmid copies in transfected cells through real-time 
PCR - 10 - 
3.2.4. Assessment of plasmid resistance to nuclease action ....................................- 11 - 
3.2.5. mRNA analysis...............................................................................................- 12 - 
3.3. In vivo testing.........................................................................................................- 12 - 
3.3.1. Animals and parasites ....................................................................................- 12 - 
3.3.2. Enzyme-Linked Immunosorbent Assay (ELISA) .............................................- 12 - 
3.3.3. Immunization DNA plasmid protocol...............................................................- 13 - 
3.3.4. Challenging test .............................................................................................- 13 - 
4. Results and discussion ..................................................................................................- 13 - 
4.1. In vitro assays........................................................................................................- 13 - 
4.2. Quantification of number of plasmid copies............................................................- 17 - 
4.3. Determination of mRNA .........................................................................................- 18 - 
4.4. In vivo assays ........................................................................................................- 19 - 
4.5. Challenge assays...................................................................................................- 22 - 
5. Conclusion and further work ..........................................................................................- 24 - 
 ii 
6. References ....................................................................................................................- 25 - 
7. Appendix .......................................................................................................................- 30 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 iii
Figures 
 
Figure 1 - Distribution of East & West African Sleeping Sickness (in 
http://www.sgpp.org/african_sleeping_sickness.shtml .................................................... - 1 - 
Figure 2 – Diagrammatic representation of the life cycle of Trypanosoma brucei in the human 
and the tsetse fly (in Kennedy, 2004).............................................................................. - 2 - 
Figure 3 - Schematic representation of the plasmid vectors pVAX1GFP, pVAX1TSAGFP, 
pVAX1TSAGFP, pVAX1TSAGFP-Synt and pVAX1TSAGFP-O2 with the restriction 
enzymes and sites used to clone the gene TSA. ............................................................ - 8 - 
Figure 4 - Transfection of HeLa cells with plasmids (a, b) pVAX1TSAGFP-BGH, (c, d) 
pVAX1TSAGFP-Synt, and (e, f) pVAX1TSAGFP-O2, observed by (a, c, e) optical and (b, d, 
f) fluorescence microscopy. ...........................................................................................- 14 - 
Figure 5 - Comparison between (a) transfection efficiencies and (b) average cell fluorescences 
of pVAX1GFPTSA, pVAX1GFPTSA-Synt and pVAX1GFPTSA-O2 plasmids transfected 
into CHO (blue bars) and HeLa (orange bars) cells. Error bars indicate standard error 
between three or five independent transfection experiments for HeLa and CHO cells, 
respectively. ..................................................................................................................- 15 - 
Figure 6 - Time-course evolution of supercoiled isoforms of the plasmid pVAX1TSAGFP SC 
during incubation at 37ºC with nucleases present in HeLa cell crude lysates at (A) pH 4.7 
and (B) pH 7. Numbers in each lane correspond to incubation time in minutes..............- 16 - 
Figure 7 - Time-course evolution of SC plasmid isoforms during incubation with nucleases at 
37ºC using HeLa cell crude lysates: pVAX1TSAGFP (◊ at pH 7 and ♦ at pH 4.7), 
pVAX1TSAGFP-O2 (□ at pH7 and ■ at pH 4.7) and pVAX1TSAGFP-Synt (∆ at pH 7 and ▲ 
at pH 4.7). The SC isoform percentage was calculated from two independent agarose gel 
analysis by normalising band intensities to incubation time zero. Error bars indicate 
standard error between the two assays. ........................................................................- 16 - 
Figure 8 - Test of different types of extracts to coat ELISA plates.Total protein extract from 
Trypanossoma brucei brucei in carbonate buffer pH 8.5 non diluted (T. brucei 16µg/µl) and 
diluted (T .brucei 1.6µg/µl). Recombinant protein TSA (200ng/well and 100 ng/well).....- 20 - 
Figure 9- IgG humoral immune response elicited by DNA vaccination. A - Groups of mice 
immunized with 50 µg of plasmid or 100 µl of phosphate buffer saline alone (control group) 
by intramuscular way. Humoral immune response was measured 12, 20, 35 and 53 days 
after immunization. B- Same groups of immunized mice discounting the optical density 
 iv 
obtained for non-immunized group (PBS). These results are represented from pool of 
serum from five animals per group.................................................................................- 21 - 
Figure 10 - Blood sample of Balb/C with Trypanosoma brucei brucei 28 days after infection. The 
staining was performed by the method Giemsa and observed with an magnification of 600x.
......................................................................................................................................- 23 - 
Figure 11 - Survival percentage of outbred Balb/C mice after infection with Trypanosoma brucei 
brucei . ..........................................................................................................................- 23 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 v 
Tables 
 
 
Table  1 - Quantification of pDNA molecules per cell by Real-Time PCR. .............................- 17 - 
Table  2 - Quantification of RNA. %T corresponds to transfection percentage; MI corresponds to 
Mean intensity; GFP corresponds to the product between %T and MI. ..........................- 18 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vi 
Abstract 
 
African Trypanosomiasis is a neglected and emergent disease, commonly known as sleeping 
sickness, caused by the protozoan parasite Trypanossoma brucei. Although the disease can be 
successfully controlled by a combination of approaches, the large number of people affected 
and at risk made the development of a vaccine an imperative. 
The use of plasmids as gene transfer vectors is a promising approach for the safe delivery of 
DNA in preventive and therapeutic vaccination. These vaccines have the advantage of inducing 
both humoral and cell-mediated immunity, causing prolonged expression of the antigen, which 
generates significant immunological memory. However, the accessibility and specific 
characteristics of the target organ may impose obstacles along trafficking and nuclear delivery 
pathway of therapeutic genes. In order to overcome such barriers, improved plasmids were 
developed in a way to maximize its survival in nuclease-rich environments. Two new constructs 
containing the N-terminal fragment of the TSA (trans-sialidase) gene from T. brucei brucei were 
obtained by modifications performed on the origin of replication (pVAX1GFP-O2) and on the 
polyadenylation signal (pVAX1GFP-Synt) (Azzoni et al., 2007). All the constructs were tested for 
efficiency of transfection in CHO and HeLA animal cells, plasmid half-life in transfected cells and 
nuclease resistance in vitro, in order to assess plasmid performance and potential advantages 
during in vivo assays. The transfection levels obtained with the TSA containing plasmids were 
comparable to the ones obtained with the pVAX1GFP control plasmid, showing that the TSA 
gene does not interfere with plasmid transfection. Plasmids pVAX1TSAGFP-O2 and 
pVAX1TSAGFP-Synt revealed higher transfection levels when compared to the non-modified 
plasmid pVAX1-TSA-GFP. Concerning cell type, the transfection levels obtained with HeLa cells 
were significantly higher than for CHO cells, in accordance with previous data (Azzoni et al., 
2007). Furthermore, mice were immunized (pVAX1-TSA-GFP, pVAX1-TSA-GFP-O2 and 
pVAX1-TSA-GFP-Synt), challenged with T. brucei and the humoral response was determined. 
Although differences in the humoral response were not clear and no protective effect was 
detected the immunized mice have shown differences on survival from the controls. 
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Resumo 
 
A doença do sono, também conhecida por Tripanossomose Humana Africana (HAT), é causada 
pelo protozoário, Trypanosoma brucei rhodensiense, na África Oriental e pelo Trypanosoma 
brucei gambiense, na África Ocidental. Embora as duas espécies sejam morfologicamente 
indistinguíveis, possuem, em termos epidemiológicos, modos de acção muito diferentes em 
ambos os tipos de HAT, a doença é transmitida pela mosca tsé-tsé, do género glossina. 
Animais selvagens e domésticos são reservatórios destes parasitas, causando assim a doença 
nos humanos. A tripanossomose é uma doença que envolve dois estadios clínicos distintos 
(Stich et al., 2002). Imediatamente após introdução no organismo humano, os tripanossomas 
multiplicam-se até atingirem o ponto de inoculação, produzindo uma reacção inflamatória local 
(chancre), e invadindo em seguida a corrente sanguínea, gânglios linfáticos e outros tecidos. 
Este ponto da doença é conhecido como estado inicial. Posteriormente verifica-se a invasão do 
sistema nervoso central, causando meningoencefalite. Este estadio denomina-se tardio. 
Quando não tratada a tripanossomose causa o coma dos pacientes ou mesmo a morte (Mclean 
et al., 2004). 
A doença tem vindo a ser controlada com sucesso, recorrendo-se para isso à combinação de 
medidas, das quais se enumeram, o tratamento de pacientes, a triagem de novos casos, bem 
como o controlo do vector. Contudo, desde 1970 que a doença tem reemergido como uma nova 
epidemia de enorme proporção, tendo sido negligenciada pela comunidade internacional até há 
pouco tempo. 
O ciclo de vida de T. brucei brucei, comum a todos os parasitas, dá-nos a conhecer a 
variabilidade morfológica, fisiológica e bioquímica que estes apresentam, traduzindo-se no 
modo de acção dos parasitas para escaparem ao sistema imunológico do hospedeiro. Esta 
notável capacidade de variação antigénica, faz com que haja uma invasão constante do 
sistema imunológico, resultando em ciclos de parasitémia (parasitas no sangue) (Kennedy, 
2005). Pensa-se que aproximadamente 10% da totalidade dos genes (cerca de 1000) codificam 
glicoproteínas de superfície variáveis (VSG). Estes genes são de elevada importância em 
termos de patogenicidade, uma vez que fornecem a base para a variação antigénica observada 
aquando da infecção por tripanossoma. Adicionalmente, a sua organização estrutural permite 
que cada proteína seja expressa de forma temporalmente coordenada, mantendo-se todos os 
outros genes transcricionalmente silenciados. As VSGs localizam-se na superfície do 
tripanossoma estando ancoradas à membrana externa através do açúcar glicosilfosfatidilinositol 
(GPI). Cerca de dez milhões de cópias de um único tipo de VSG cobrem a superfície do 
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tripanossoma num dado momento (Kennedy, 2004). Esta variação antigénica permite que o 
parasita evada constantemente da resposta imunitária do hospedeiro. 
O tratamento da HAT constitui um grande desafio. A formulação de meios de tratamento 
continua a estar fortemente afectada por vários factores de que são exemplo: pobreza e más 
infra-estruturas; alterações do habitat da mosca tsé-tsé; diagnósticos e ensaios clínicos 
deficientes. Assim, na ausência de uma vacina contra a tripanossomose Africana, e tendo em 
conta a crescente resistência dos tripanossomas às drogas orais existentes (Suramin; 
Pentamidine; Melarsoprol; Eflormithine; Nifurtimox), o meio de controlo da doença, mais 
promissor, ainda que teoricamente, envolve o controlo da população de vectores (Bouteille et 
al., 2003; Kennedy., 2004). Embora para tal existam várias técnicas, o método mais efectivo 
continua a ser o uso de insecticidas. Sendo o desenvolvimento de fármacos orais difícil e 
moroso e atendendo ao conhecimento já adquirido face ao mecanismo de evasão dos 
parasitas, o que dificulta a obtenção de uma vacina efectiva, torna-se crucial o desenvolvimento 
de uma nova estratégia de vacinação. Neste contexto, as vacinas de DNA apresentam-se como 
uma forte alternativa, atendendo aos resultados promissores que têm vindo a ser revelados na 
prevenção de outras doenças infecciosas. 
As vacinas de DNA, embora recentes e na sua maioria ainda experimental, têm-se mostrado, 
até à data, efectivas. Tal como no caso das vacinas recombinantes, os genes que codificam 
para os antigenioss pretendidos são triados e clonados num vector plasmídico. No caso das 
vacinas de DNA, o DNA é injectado no músculo do animal. A expressão do gene relevante 
contido no DNA plasmídico inoculado no hospedeiro, produz então a proteína antigénica 
responsável pela resposta imunitária (Robinson, 1997). 
Os resultados obtidos com as vacinas de DNA revelam que estas possuem potencialidades no 
combate de doenças infecciosas, cancro e alergias. A vacinação genética tem sido também 
utilizada com sucesso na produção de antitumor e de antiidiotipo, e em respostas aloimunes. 
Para além disso verificou-se que a utilização desta estratégia estava envolvida na supressão da 
doença experimental de autoimunidade, encefalomielite alérgica, bem como na inibição de 
respostas alérgicas (Tighe et al., 1998).  
As vacinas de DNA mostram numerosas vantagens face aos outros tipos de vacinas 
(atenuadas; vivas). Por exemplo, a proteína de interesse é expressa no hospedeiro na sua 
forma natural, ou seja, não se verifica desnaturação nem modificação, e a resposta imunitária é 
dirigida ao antigénio exactamente como se fosse expressa pelo agente patogénico. Estas 
vacinas são ainda capazes de induzir, quer resposta humoral, quer citotóxica, ao contrário das 
restantes vacinas, que para estimular ambas as vias de resposta imunitária necessitam de 
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imunização com preparações vivas/atenuadas, as quais introduzem fortes riscos. A estratégia 
de imunização referida causa expressão prolongada do antigénio gerando memória 
imunológica. Embora não sejam uma solução universal para os problemas da vacinação, por 
exemplo nas infecções por pneumococos e meningocos, é crucial a protecção com antigénios 
polissacáridos (Goldsby et al., 2006) e não proteicos como os obtidos por estas vacinas. É 
suposto, no entanto, que com o desenvolvimento acentuado desta estratégia, as vacinas de 
DNA baseadas em plasmídios (vectores não virais) serão nos próximos anos utilizadas na 
imunização Humana. 
O objectivo principal deste trabalho consistiu na construção, optimização e avaliação de um 
protótipo de vacina de DNA contra a Tripanossomose Africana, com resistência melhorada a 
nucleases. O projecto envolveu a colaboração de duas instituições, o Centro de Engenharia 
Biológica e Química (CEBQ/IBB), do Instituto Superior Técnico e o Instituto de Higiene e 
Medicina Tropical (IHMT), da Universidade Nova de Lisboa. 
Como referido anteriormente, a utilização de plasmídios como vectores de transferência de 
genes é uma estratégia promissora na introdução do DNA através da vacinação preventiva e 
terapêutica. Contudo, a acessibilidade e as características dos órgãos-alvo podem-se traduzir 
em obstáculos ao tráfego e introdução nuclear dos genes terapêuticos. Para ultrapassar essas 
barreiras foram desenvolvidos plasmídios melhorados, de forma a maximizar a sua 
sobrevivência, face a ambientes ricos em nucleases. Assim, duas novas construções contendo 
a região terminal N do gene TSA de tripanossoma T. brucei brucei foram obtidas por 
modificação da origem de replicação (pVAX1GFP-O2) e do local de poliadenilação 
(pVAX1GFP-Synt) (Azzoni et al., 2007). As construções utilizadas neste estudo, foram 
submetidas a testes de resistência a nucleases, in vitro, de modo a avaliar o tempo de  semi-
vida dos plasmídios nas células transfectadas, bem como a eficácia de transfecção das células 
animais CHO e HeLa, simulando assim, o comportamento in vivo dos protótipos. 
Os níveis de transfecção obtidos para estas novas construções demonstraram ser comparáveis 
aos resultados obtidos para pVAX1GFP, demonstrando que o gene TSA não interfere na 
transfecção. Os valores obtidos para os plasmidios pVAX1TSAGFP-O2, pVAX1TSAGFP-Synt 
foram mais elevados, comparativamente ao plasmidio não modificado pVAX1TSAGFP. Os 
níveis de transfecção foram mais elevados quando se utilizaram células HeLa do que com 
células CHO, sendo concordantes com dados previamente publicados (Azzoni, et al., 2007). 
Também se imunizaram ratinhos Balb/C com pVAX1TSAGFP, pVAX1TSAGFP-O2 e 
pVAX1TSAGFP-Synt, os quais foram infectados posteriormente com T. brucei, para a 
quantificação da resposta humoral. Os resultados obtidos por imunodetecção pela técnica de 
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ELISA (enzyme-linked immunosorbent assay), não foram claros nem mostraram um efeito 
protector da vacina. Contudo, os ratinhos imunizados mostraram alguma diferença em termos 
de taxa de sobrevivência, comparativamente ao controlo. 
 
 
Palavras-Chave: Vacina de DNA; Plasmidio; Resistência às nucleases; Transfecção; 
Transferência genética. 
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1. Introduction 
 
1.1. Human African Trypanosomiasis  
 
Sleeping sickness, also known as Human African Trypanosomiasis (HAT), is caused by the 
action of a protozoan, namely, Trypanosoma brucei rhodensiense in Eastern Africa and 
Trypanosoma brucei gambiense in Western Africa (Figure 1). Both protozoan species are 
morphologically indistinguishable, but have 
drastically different epidemiological features. In 
both types of HAT the disease is transmitted by 
the blood-sucking tsetse fly of the genus 
Glossina. Infected wild animals and domestic 
animals, such as cattle, are the reservoirs of 
parasites causing human disease. Human African 
trypanosomiasis is a disease that evolves through 
clinically distinct stages (Stich et al., 2002). 
Immediately after penetration into the human 
organism, the trypanosome multiplies at the point 
of inoculation, producing a local inflammatory 
reaction causing local inflammation (chancre), 
and subsequently invades the bloodstream, 
lymph nodes, and other tissues. When the 
parasites invade the central nervous system, the 
stage of the disease it is known as 
meningoencephalitic, or late. Without treatment, 
the disease progresses to coma and eventually death (Mclean et al., 2004). 
The fly remains infective for life, and human/fly contact is therefore a crucial component of the 
disease. The life cycle of the Trypanossoma sp. organism in the human organism and in the 
tsetse fly is summarized in Figure 2 (Kennedy, 2004). 
The disease has been successfully controlled by a combination of approaches, including 
treatment of patients, active case finding, and measures to deal with the vector. Since the 
1970s, however, HAT re-emerged as a new epidemic of immense proportions, which, until 
recently, received little attention from the international community.  
 
 
 
 
 
 
 
 
 
 
 
 
     
 
 
Figure 1 - Distribution of East & West 
African Sleeping Sickness (in 
http://www.sgpp.org/african_sleeping_sickne
ss.html  
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Figure 2 – Diagrammatic representation of the life cycle of Trypanosoma brucei in the human and the 
tsetse fly (in Kennedy, 2004). 
 
 
 
According to the World Health Organization, about 500 000 people already carry trypanosomes 
and currently 60 million people are at risk of contracting the disease (Stich et al., 2002). 
Throughout its life cycle, T. brucei, undergoes several morphologic, physiologic, and biochemical 
changes, which help the survival of the parasite in a great range of hosts. A critical feature of the 
trypanosomes is their remarkable ability to undergo antigenic variation and thereby to constantly 
evade the immune response of the host, resulting in waves of parasitaemia (parasites in the 
blood) (Kennedy, 2005). It is thought that 10% of the total genome (around 1000 genes) is 
variant surface glycoprotein (VSG) genes encoding variable surface glycoproteins. The VSG 
genes are of great pathogenic importance as they provide the molecular basis for the antigenic 
variation seen in trypanosome infection. Only one of the genes is expressed at any one time, the 
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rest being transcriptionally silent. The VSGs are distributed over the surface of the trypanosome 
and are anchored to the outer membrane by a glycosylphosphatidylinositol (GPI) anchor. Ten 
million copies of a single species of VSG cover the trypanosome surface at any one time 
(Kennedy, 2004). This antigenic variation allows the parasite to continuously evade the host’s 
immune response. 
 
1.2. Immunologic system and interaction with Trypanosomes  
  
The immune system is responsible for the capability of an organism to resist to an infection. Two 
types of responses are known: i) the innate response and ii) acquired response (Madigan et al., 
1997). 
The innate response is characterized by a non-specific response that operates against a wide 
range of substances. No prior exposure is necessary to stimulate the immune response and 
cells like monocytes/macrophages, neutrophiles and natural killer cells are immediately available 
to combat the unfamiliar substances. Therefore, this type of immune reaction forms the basis of 
the first line of defence in an organism. 
Acquired immunity is a more specialised form of the immune response. The main difference 
between innate and acquired immunity is the ability of lymphocytes to recognise particular 
antigens in a specific manner. This is made possible through the presence of cell surface 
receptors on the lymphocytes that recognise discrete parts of an antigen known as epitopes. 
The two main cell types associated with the acquired immune response are the T-lymphocytes 
or T-cells, including CD4+ and CD8+ cell subsets, and the B-Lymphocytes or B-cells. T-cells 
carrying the CD4 surface marker mainly perform functions that “help” or “induce” an immune 
reaction known as T-helper (Th). These Th can be divided in two subgroups: i) Th1 and Th2. 
The subgroups can be distinguished by the array of cytokines that they produce such as IL-2 
and IFN-y. Th1 cells are particularly important for the eradication of intracellular pathogens 
including bacteria, parasites, yeast and viruses and will react to an antigen only if it is presented 
in conjunction with MCH class II molecules. In addition, Th1 response can result in the activation 
of natural killer and CD8 T-cells. Th2 cells produce cytokines such as IL-4, IL-6 and IL-10 that 
consequently induce B-cell proliferation, antibody production and eosinophil and mast cell 
activation. Hence, Th1 cells are predominantly associated with cell-mediated immunity, while 
Th2 cells induce strong antibody and allergic responses.  
T-cells that express the CD8 cell surface marker are predominantly cytotoxic in function and are 
thefore known as T-cytotoxic (Tc) cells.  When activated Tc cells recognize pathogen-derived 
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peptides, and in conjunction with MHC class I molecules, they induce the cell to undergo 
apoptosis, resulting in the death of the infected cell.  
The antibodies responsible for the protection of the host are produced by the B-lymphocytes or 
B-cells (Janeway and Travers, 1996; Roitt et al., 2001). B-cells comprise approximately 5 to 15% 
of the circulating population and can be defined by the presence of cell surface IgM and IgD. 
Therefore a particular B-cell will only react with one distinct antigen and will ultimately produce 
that antibody. In addition the surface antibody helps to deliver bond-antigen to the interior of the 
B-cell where it is processed and returned to the cell surface in conjunction with MHC – II 
molecules for presentation to either naïve or primed T-cells.  
In general, naïve B-cells do not became activated following an encounter with antigen alone and 
require assessorial signals to complete the transition from naïve to activated, differentiated cells. 
These assessorial signals can be generated by either armed CD4+ cells or directly by certain 
microbial constituents. Therefore, B-cells are said to be activated either by a T-cell dependent or 
by a T-cell dependent antigen.  
The immunosupression mechanism developed during the trypanossome infection is one of the 
main mechanisms of evasion of the host immunologic system, together with VSG. This process 
consists in the incapacity of the T-cell to proliferate. The trypanossome has the capacity to 
modulate the immunological response to their one benefit through the secretion of certain 
factors known as trypanokines as the case of TLTF (T lymphocyte triggering factor) (Olsson et 
al., 1993). This molecule is able to activate T CD8+ cells which induce the production of IFN- y. 
On the other hand, the infection by Trypanosome increases the number of macrophages and 
their activation as result of the contact between the cells and the different components of the 
parasite, especially, VSG (Paulnock and Coller, 2001).  
Another strategy for the adaptation of the parasite to the host is the induction of Trypanosome 
brucei proliferation by IFN- y (Olsson et al., 1993, Nishimura et al., 2004). This effect is inhibited 
by anti-IFN-y-receptor antibodies and it can not occur after contact with other cytokine (IFN-α, 
IFN-β or TNF-α).  
 
1.3. Vaccine types 
 
As described before the T. brucei has a remarkable mechanism of defence, due to the variable 
surface glycoprotein (VSG) gene switching process, which provides a great antigenic variation. 
Due to this switching, the parasite can evade constantly the natural defences of the host. This 
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mechanism has made it impossible to develop an effective vaccine until now. As a result, new 
approaches have been pursued, and amongst these, the vaccination strategy with plasmid DNA 
has revealed some promising results. 
There are three main groups of vaccines: live vaccines, which can be further, divided in two 
subgroups (attenuated and recombinant); inactivated (killed) vaccines; and DNA vaccines. 
In some cases, microorganisms can be attenuated so that they lose their ability to cause 
significant disease (pathogenicity) but retain their capacity for transient growth within an 
inoculated host, inducing therefore an immune response (Hassett and Whitton, 1996). Because 
of their capacity for transient growth, such vaccines provide prolonged immune-system exposure 
to the individual epitopes on the attenuated organisms, resulting in increased immunogenicity 
and production of memory cells. As a consequence, these vaccines often require only a single 
immunization, eliminating the need for repeated boosters. Some examples of attenuated 
vaccines are flu, rabies, Salk polio vaccine, among others (Janeway et al., 2005). A major 
disadvantage of attenuated vaccines is the possibility that they might revert to a virulent form. 
Attenuated vaccines may also be associated with complications similar to those seen in the 
natural disease. A small percentage of recipients of the measles vaccine, for example, develop 
post-vaccine encephalitis or other complications (Goldsby et al., 2006). 
Several live recombinant vaccines, either viral or bacterial, have been developed to counter a 
great number of infectious diseases. These vaccines use virus or bacteria which do not express 
virulence, but makes the immune system responding accordingly. An example of recombined 
vaccine is the vaccine against rotavirus, a major cause of infant diarrhoea, which was developed 
using genetic engineering techniques to modify an animal rotavirus to contain antigens present 
on the human viruses (Goldsby et al., 2006). 
Another common approach in vaccine production is inactivation or even death of the pathogen 
by heat or by chemical means so that it is no longer capable of replication in the host. These 
vaccines are usually called inactivated or “killed” vaccines. One of the disadvantages of killed 
vaccines is that they often require repeated boosters to maintain the immune status. Attenuated 
vaccines, on the other hand, usually need only one dose to induce immunity over a long period 
of time.  
The majority of DNA vaccines are still experimental. Nonetheless, there are at the moment three 
DNA vaccines approved for animals, namely for necrosis in salmons and towards the West Nile 
virus in horses and dog melanoma (Davis et al., 2001; Mikalsen et al., 2005). Like in the case of 
recombinant vaccines, genes coding for the desired antigens are located and cloned. In the 
case of DNA vaccines, however, the DNA is injected into the muscle of the animal being 
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vaccinated. The expression of the relevant gene in the inoculated host produces the protein that 
raises the immune response (Robinson, 1997). Several features of DNA vaccines indicate their 
enormous future potential in diverse fields such as infectious diseases, allergy and cancer.  
Gene vaccination has also been successfully used to elicit antitumor, antiidiotype and 
alloimmune responses (Geissler, 1994). In addition, this strategy has been found to suppress 
the autoimmune disease experimental allergic encephalomyelitis and to inhibit allergic 
responses (Tighe et al., 1998).  
DNA vaccines offer advantages over many of the existing vaccines. For example, the encoded 
protein is expressed in the host in its natural form - there is no denaturation or modification. The 
immune response is therefore directed to the antigen exactly as it is expressed by the pathogen. 
DNA vaccines also induce both humoral and cell-mediated immunity; to stimulate both arms of 
the immune response with non-DNA vaccines normally requires immunization with a live 
attenuated preparation, which introduces additional elements of risk. Finally, DNA vaccines 
cause prolonged expression of the antigen, which generates significant immunological memory. 
DNA vaccines will likely be used for human immunization within the next few years. However, 
they are not an universal solution to the problems of vaccination; for example, only protein 
antigens can be encoded, and certain vaccines, such as those for pneumococcal and 
meningococcal infections, use protective polysaccharide antigens (Goldsby et al., 2006). 
Concerning the vaccine used in this particular study, it was constructed in order to express an 
enzyme, trans-sialidase (TSA), which is present in T. cruzi, conferring the parasite their evasive 
capability. In T. brucei similar enzymes are encountered, but their role is not yet fully understood 
(Barret et al., 2003). TSA is involved in the transfer of sialic acid to the terminal galactose of 
mucines that coats the surface of the parasites. The presence of this residue alters the biological 
properties of the protein surface molecules and consequentially the parasite-host cell interaction 
as well as the activation of T-cells (Tribulatti et al., 2004). The action of antibodies after the 
infection period towards these proteins prevents a massive invasion of cells by the parasites, 
(Frasch, 2000). 
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2. Work aims  
 
The main objective of the work was the construction, optimization and testing of African 
Trypanosomiasis DNA vaccine prototypes with improved nuclease resistance, based on the 
expression of TSA. The project involved the collaboration of two institutions, the “Centro de 
Engenharia Biológica e Química (CEBQ)/(IBB) - Institute for Biotechnology and Bioengineering 
at Instituto Superior Técnico and Instituto de Higiene e Medicina Tropical (IHMT), Universidade 
Nova de Lisboa.  
 
3. Materials and Methods 
 
3.1. Construction of DNA vaccine prototypes with increased nuclease resistance 
3.1.1. Plasmid construction 
 
All the vectors were based on commercially available plasmid vector pVAX1LacZ (6050 bp, 
Invitrogen), designed to be used in the development of DNA vaccines (Invitrogen). This vector 
contains the human cytomegalovirus (CMV) immediate early promoter, the bovine growth 
hormone polyadenylation (BGH polyA) sequence, a kanamycin resistance gene for selection in 
Escherichia coli, a pMB1 origin (pUC-derived), a multiple-cloning site, a T7 promoter/priming site 
and β-galactosidase as a reporter gene (Montgomery et al., 2006). The lacZ reporter gene was 
replaced by the eGFP (enhanced Green Fluorescent Protein) gene obtained from the plasmid 
pFM20 (Carapuça et al., 2007), yielding the plasmid vector pVAX1GFP (3697 bp). Having in 
consideration that the BGH polyA sequence and the pMB1 origin of replication are regions more 
susceptible to exo/endonucleases action, new plasmid vectors were constructed: pVAX1GFP-
Synt was obtained by replacing the BGH polyA region by a synthetic polyA (Azzoni et al., 2007); 
and pVAX1GFP-O2 was a result of site directed mutagenesis of the pMB1 origin of replication in 
which seven nucleotides were mutated (Azzoni et al 2008). Afterwards the pVAX1GFP, 
pVAX1GFP-Synt and pVAX1GFP-O2 plasmids were cloned with the N-terminal fragment of the 
trans-Sialidase TSA gene from the Trypanossoma brucei brucei, giving rise to the plasmid 
vectors pVAX1TSAGFP (5112 bp), pVAX1TSAGFP-Synt (4903 bp) and pVAX1TSAGFP-O2 
(5112 bp). These last constructions and the pVAX1GFP were used in the present work (Figure 
3). 
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3.1.2. Bacterial transformation 
 
Escherichia coli DH5α cells were transformed with the referred plasmids. This was performed by 
adding the plasmid DNA to competent cells and keeping the mixture in ice for 30 minutes, after 
which the mixture was heated during one minute at 42ºC and then immediately cooled down on 
ice for 2 minutes. The mixture was placed in 1 mL of Luria-Bertani (LB) medium and incubated 
for 40 minutes to one hour at 37ºC. The culture was then centrifuged at 2655g for two minutes 
and the obtained cell pellet was plated on LB plates containing kanamycin for selection of 
transformed E. coli colonies and incubated overnight. The transformed colonies were mixed in 
one mL of LB medium containing glycerol (20% v/v) and kept at -80ºC until needed. 
In order to obtain plasmid DNA solutions, transformed E. coli Dh5-α were grown overnight on 5 
mL of LB medium containing kanamycin (30 mg.mL-1) at 37 ºC in an orbital shaker at 250 rpm. 
Plasmids were extracted using the High Pure Plasmid isolation kit, following manufacturer’s 
instructions (Roche, Germany), and kept at 4ºC. The concentration of plasmid DNA of the 
purified solution was determined using a NanoDrop ND-1000 spectrophotometer (Thermo 
Scientific, USA). Moreover, the ratio between the measured absorbance at 260 nm and 280 nm 
gave additional information regarding to the purity of the solution (the optimal ratio is 1:8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 - Schematic representation of the plasmid vectors pVAX1GFP, pVAX1TSAGFP, pVAX1TSAGFP, 
pVAX1TSAGFP-Synt and pVAX1TSAGFP-O2 with the restriction enzymes and sites used to clone the gene TSA. 
 - 9 - 
 
3.2. In vitro testing 
3.2.1. Mammalian cell culture and Transfection 
 
Cell cultures were performed in standard 75 cm2 tissue culture flasks and incubated at 37ºC in 
5% CO2 humidified environment. CHO and HeLa cells were cultivated and maintained in F-12 
(Ham’s) nutrient mixture (Gibco, UK) containing 10% (v/v) foetal bovine serum (FBS; Gibco, UK) 
supplemented with non-essential aminoacids (Gibco, UK), gentamicin (Gibco, UK), sodium 
pyruvate (Gibco, UK) and antibiotic-antimycotic (Gibco,UK). When culture reached confluence, 
cells were washed in phosphate-buffered saline (PBS) and trypsinized using a 0.05% trypsin-
EDTA (Gibco, UK) solution. Cells were then harvested, seeded in 24 well culture plates (5x104 
cells per well) and incubated for 24 hours. After that the medium was exchanged to OptiMEM 
(Gibco,UK) medium without serum or antibiotics and cells were transfected with the different 
plasmids using 1.5 µL of Lipofectamine 2000TM reagent (Invitrogen, UK) and 1µg of plasmid 
DNA per well, following the manufacturer’s instructions. For these transfection assays only 
plasmid DNA solutions with a concentration higher than 100 µg.µL-1 were used. The negative 
control consisted on using transfection reagents without the presence of plasmid DNA. After 6 
hours, the medium was replaced by F-12 medium as described above. It should be emphasized 
that the transfection method using Lipofectamine 2000TM had already been previously 
optimized, namely in terms of plasmid to reagent ratio and incubation times, and the same 
conditions were followed for the Fugene HD transfection to allow a preliminary comparison 
between the reagents. 
 
3.2.2. Assessment of fluorescent protein expression by Flow Cytometry 
analysis and Fluorescence Microscopy 
 
The transfection of the different plasmids using both reagents, as detailed above, was followed 
using flow cytometry. Twenty-four hours following transfection, cells were rinsed twice in PBS, 
trypsinized and collected. The obtained cell pellet was ressuspended in 45.0 µL of PBS 
containing 4% FBS. The suspension was used for the flow cytometry assays performed in a 
FACScan Scalibur (Becton-Dickson, USA). Transfected and non-transfected cells were analysed 
for forwards scatter (FSC), side scatter (SSC) and green fluorescence (FL1). From the collected 
data, cells were first isolated from debris by their FSC versus SSC characteristics defining a 
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gate. Transfection efficiency was determined by subtracting those cells displaying background 
FL1 (nontransfected cells) from the total cell population present within the gate. Average green 
fluorescence intensities corresponding to the expression of GFP fusion proteins were calculated 
using the CellQuest Pro software (Becton-Dickson, USA). The transfection level was defined as 
the percentage of cells that presented green fluorescence above the auto-fluorescence 
threshold of the negative control and was determined also using the CellQuest Pro software. 
Transfected cells were also observed under a fluorescence microscope using an Olympus CK40 
(UK) microscope and pictures were taken with visible and UV light using a Nikon DXF1200F 
camera. 
 
3.2.3. Determination of number of plasmid copies in transfected cells through 
real-time PCR 
 
The number of plasmid DNA copies present per transfected cell was quantified using a real-time 
PCR method (Carapuça et al., 2007). Twenty-fourhours after transfection, cultures were washed 
three times with 0.8 mL of PBS to remove plasmid DNA non-specifically bounded. Afterwards 
cells were trypsinized and centrifuged at 160xg for 8 min at 4ºC. The obtained pellets were 
washed with PBS and ressuspended in 1 mL of PBS. Cell density was determined using a 
Neubauer chamber (each count was performed in duplicate). Afterwards cells were again 
centrifuged under the same conditions to remove the supernatant and the pellets were stored at 
-80ºC. Prior to performing the RT-PCR assay pellets were ice-thawed and resuspended in PCR 
grade deionized water in order to obtain a concentration of 3125 cell/µL. Two µL of this 
suspension were used to quantify the plasmid content. The negative control consisted in cells 
incubated with the transfection reagents without the presence of plasmid DNA. The 
quantification was performed using a calibration curve, which was obtained by pre-set 
concentrations of only the purified pVAX1GFP and also of the plasmid added to the control cells. 
An internal control of the PCR reaction was composed using only the cells. The quantification of 
plasmid DNA was based on the amplification of a sequence from the Kan gene using the 
forward primer 5’-AGA CAA TCG GCT GCT CTG AT-3’ and the reverse primer 5’-CAA TAG 
CAG CCA GTCCCT TC-3’. The assays were carried out in a Roche LightCyclerTM detection 
system, using the FastStart DNA Master SYBR Green I kitTM (Roche, Germany). Each 20 µL of 
final reaction volume contained 2.0 µL of SYBR Green mixture, 0.4 µL of each primer (0.4 µM 
final concentration), 1.6 µL of MgCl2 solution (3.0 mM final concentration), 13.6 µL of PCR-grade 
water, and 2.0 µL of sample. Reaction mixtures were incubated at 95 ºC for 10 minutes to 
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activate FastStart DNA polymerase, followed by 45 cycles of 10 seconds at 95 ºC, 5 seconds at 
54 ºC, and 10 seconds at 72 ºC. After the final cycle, reaction mixtures were kept at 70 ºC for 30 
seconds, and cooled down at 40ºC for 30 seconds. 
 
3.2.4. Assessment of plasmid resistance to nuclease action 
 
The resistance of the different plasmid constructs to the action of nucleases was assessed using 
CHO and HeLa cell lysates. In order to prepare cell lysates, confluent CHO and HeLa cells 
grown in 75 cm2 tissue culture flasks as described previously, were trypsinized and centrifuged 
at 160xg for 8 min at 4ºC. The pellet was carefully washed twice with PBS, and then suspended 
in PBS and again centrifuged under the same conditions (the presence of trypsin could damage 
the nucleases afterwards). Finally the cell pellet was resuspended in 3 mL of 30 mM sodium 
acetate, 50 mM sodium chloride and 2.1 mM of magnesium chloride at pH 4.7 to study plasmid 
degradation by endo/lysosomal nucleases or at pH 7 to test degradation by cytoplasmatic 
nucleases. Cell suspensions were maintained on ice and then sonicated by applying two 
constant pulses of 15 seconds (with a one minute interval in between in order to cool down the 
suspensions and therefore prevent nuclease degradation). The obtained lysates were 
centrifuged for 10 minutes at 13000xg and the supernatant was collected. Aliquots of the crude 
lysate were kept at -20ºC until needed. 
The CHO lysate at pH 4.7 was diluted 1:10 in the respective buffer described above and the 
CHO lysate at pH 7 was diluted 1:5. The HeLa lysate at pH 4.7 was diluted 1:20 while the lysate 
at pH 7 was also diluted 1:5. Each plasmid (2.5 µg) was incubated at 37ºC with 37.5 µL of the 
diluted lysates and aliquots were taken at determined time intervals. The digestion was stopped 
by adding EDTA solution to a final concentration of 20 mM on ice. After collecting all samples, 
they were examined by performing a 1% agarose gel electrophoresis run at 80 V in TAE buffer 
(40mM Tris base, 20 mM acetic acid, pH 8.0, 1 mM EDTA). The obtained agarose gel was then 
stained for at least 15 minutes in a 1 µg.mL-1 ethidium bromide solution. In order to study the 
variation of the supercoiled (SC) conformation during the incubation with nucleases, the 
intensities of the corresponding bands in the gels were determined using densitometry software 
(AlphaEaseFCTM from Alpha Innotech Corporation). 
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3.2.5. mRNA analysis 
 
The mRNA was quantified by using a relationship between mean intensity and transfection 
percentage obtained by flow cytometry as described above and plasmid values obtained by real 
time-PCR (appendix 1). 
 
3.3. In vivo testing        
 
3.3.1. Animals and parasites 
 
Balb/C mice used in this work were obtained from Instituto de Higiene e Medicina Tropical, 
Lisbon – Portugal. These mice were used in the experimental infection with Trypanosoma brucei 
brucei and DNA immunization protocols. Trypanosoma brucei brucei VGR 35/1.6 parasites were 
developed in infection in mice (Autoguia, 1995).  
 
3.3.2. Enzyme-Linked Immunosorbent Assay (ELISA) 
 
Total IgG antibodies were measured by ELISA (enzyme linked immunosorbent assay) using 
serum samples from immunized DNA vaccine-mice and control group. Previously, 96-well micro-
plates (Nunc – Denmark) were coated with 100 ng.well-1 of total protein extract from 
Trypanosoma brucei brucei in carbonate buffer pH 8.5 overnight at 4ºC. The micro-plates were 
washed three times with PBS/0.05% Tween 20 (Promega – USA) and then blocked for one hour 
at room temperature with 5% (w/v) powder milk suspension in PBS. After three wash-ups, serial 
dilution of the sera pool from immunized mice were added in duplicate to the plates and 
incubated for two hours at room temperature with horseradish peroxidase (HRP)-conjugated 
antibodies: anti-mouse IgG (Sigma Chemical Co – USA) diluted 1:4000. The HRP-conjugated 
antibodies containing micro-plates were developed for 30 minutes with substrate solution: 10 mL 
of citrate buffer pH 5.0 with 10 mg of OPD and 10 µL of hydrogen peroxide 30% v/v. The final 
reaction was stopped by adding of 4N sulfuric acid and the optical density was measured at 490 
nm. 
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3.3.3. Immunization DNA plasmid protocol 
 
The DNA vaccines prototypes were purified previously by hydrophobic interaction and size 
exclusion chromatography and injected to immunize outbred Balb/C mice. All animals (group of 
five) were injected intramuscularly three times, at 0, 21, and 35 days with 50 µg of plasmid DNA. 
Control group with five animals were injected with PBS. Sera samples were collected through 
terminal tail weekly after the first immunization, pooled and stored at -20 ºC for ELISA test.  
 
3.3.4. Challenging test 
 
The assay consists on the infection of outbred Balb/C mice. The immunized mice were 
challenged with the infecting form of Trypanossoma brucei, by intraperioneal injection. Each 
mouse received an injection of 2.5 parasites/µl of PBS/Glucose 20mM. The infection took place 
three months after Immunization and the parasites used in this challenge assay come from a 
stabilate of Trypanossoma brucei brucei  (VGR 35 1.6).The survival of the infected animals 
were registered daily.  
 
 
4. Results and discussion 
 
4.1. In vitro assays 
 
In order to obtain a DNA vaccine prototype for African Trypanosomiasis, a fragment of TSA gene 
was cloned in the plasmids pVAX1TSAGFP, pVAX1TSAGFP-Synt and pVAX1TSAGFP-O2. On 
one hand, these plasmids were chosen due to their capability to resist nucleases (Azzoni et al 
2007 and 2008) and on the other hand TSA was used since it is a common membrane protein 
present in all Trypanossoma sp.. After determining and analyzing the best conditions for cell 
culture in wells and transfection, the pVAX1TSAGFP, pVAX1TSAGFP-Synt and 
pVAX1TSAGFP-O2 vectors were transfected into HeLa and CHO cells (figure 4). CHO cells are 
derived from Chinese hamster ovary and HeLa are immortal cell line derived from cervix cancer 
cells, both used in medical research. 
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Figure 4 - Transfection of HeLa cells with plasmids (a, b) pVAX1TSAGFP-BGH, (c, d) pVAX1TSAGFP-
Synt, and (e, f) pVAX1TSAGFP-O2, observed by (a, c, e) optical and (b, d, f) fluorescence microscopy. 
 
The transfection levels of HeLa cells are significantly higher than for CHO cells according with 
previously reported data (Azzoni et al, 2007). Moreover, the tranfection ratio between 
pVAX1TSAGFP and pVAX1TSAGFP-Synt and pVAX1TSAGFP-O2 is comparable to the 
previous data obtained between pVAX1GFP-BGH and pVAX1GFP-Synt and pVAX1GFP-O2 
transfection level for CHO cells (Azzoni et al., 2007 and 2008). The effects of polyadenylation 
efficiency and of modified origin of replication on transgene expression discussed by Azzoni and 
coworkers were also confirmed in the present study. The transfection levels obtained with the 
three plasmids were significantly lower than those obtained with the correspondingly plasmids 
before the insertion of the TSA gene. This agrees with other results that show that smaller 
plasmids copies are associated with improved transfection efficiency (Kreiss et al, 1999; Yin et 
al, 2005). 
The average cell fluorescence results obtained in CHO and HeLa cells are consistent between 
themselves, with fluorescence decreasing as a function of the plasmid used for transfection in 
the order pVAX1GFP-TSA > pVax1TSAGFP-O2> pVAX1TSAGFP-Synt in both cases (figure 
5b). The values of average cell fluorescence obtained here are significantly lower than those 
reported previously for the correspondent plasmids before the insertion of the TSA gene (Azzoni 
et al., 2008). This might also be related with the referred effect of increased pDNA size (Figure 
5). Therefore, the insertion of the TSA gene leads to an increase of the vector size, which limits 
the expression of the fluorescence fusion protein. The larger size of the transcript could: i) lower 
the transcription efficiency, ii) increase its degradation, iii) lower the fluorescence of the fusion 
protein, and iv) originate a fusion protein with a lower half-life. 
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Figure 5 - Comparison between (a) transfection efficiencies and (b) average cell fluorescences of 
pVAX1GFPTSA, pVAX1GFPTSA-Synt and pVAX1GFPTSA-O2 plasmids transfected into CHO (blue bars) 
and HeLa (orange bars) cells. Error bars indicate standard error between three or five independent 
transfection experiments for HeLa and CHO cells, respectively. 
 
Nuclease resistance is a major concern in DNA vaccination that requires improvement 
(Lechardeur et al., 2005). The efficacy of pDNA vaccines should be verified once intramuscular 
DNA delivering vaccination may employ different mechanism in inducing immune responses 
(Leitner et al., 2000). In addition, their capacity to induce a broad spectrum of cellular and 
humoral immune response to the protein that is encoded on the plasmid should be evaluated 
(Glenting and Wessels, 2005). In this case, the protein that is encoded on the plasmid vector 
that would trigger the immune response against HAT’s disease is expressed by the TSA gene.  
Besides changes in the polyA tail, alterations in the origin of replication, as the ones engineering 
into the pVax1TSAGFP-O2 plasmid, can produce modifications on plasmid nuclease resistance 
and, accordingly, improve their capability of reaching the nucleus in an intact form. 
The resistance of each plasmid towards nucleases present in CHO and HeLa crude cell lysates 
at pH 4.7 and pH 7 was assessed by in vitro incubations at 37ºC. The SC isoform percentage 
was calculated from two independent agarose gel analysis by normalising band intensities to 
incubation time zero. An example of the agarose gels obtained is shown in Figure 6, and the full 
data set obtained is shown in Figure 7. 
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Figure 6 - Time-course evolution of supercoiled isoforms of the plasmid pVAX1TSAGFP SC during 
incubation at 37ºC with nucleases present in HeLa cell crude lysates at (A) pH 4.7 and (B) pH 7. Numbers 
in each lane correspond to incubation time in minutes. 
 
 
Overall it can be seen that degradation of SC isoforms by nucleases at pH 4.7, which is 
representative of the endo/lysosomal compartment, was faster when compared with degradation 
at a cytoplasmatic pH of 7 (nucleases at pH 4.7 were even more diluted than cytoplasmatic 
ones). This pattern is not in agreement with that presented by Azzoni and coworkers for 
pVAX1GFP variants, although the TSA gene was not present in these constructs and the pDNA 
sizes were quite smaller (Azzoni et al.,2007). 
 
 
Figure 7 - Time-course evolution of SC plasmid isoforms during incubation with nucleases at 37ºC using 
HeLa cell crude lysates: pVAX1TSAGFP (◊ at pH 7 and ♦ at pH 4.7), pVAX1TSAGFP-O2 (□ at pH7 and ■ 
at pH 4.7) and pVAX1TSAGFP-Synt (∆ at pH 7 and ▲ at pH 4.7). The SC isoform percentage was 
calculated from two independent agarose gel analysis by normalising band intensities to incubation time 
zero. Error bars indicate standard error between the two assays. 
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As it can be observed in Figure 7, the pVAX1TSAGFP-O2 plasmid variant was more resistant 
than pVAX1TSAGFP toward nuclease action at pH 7 for both CHO and HeLa lysates, although it 
is not possible to take statistically significant conclusions with only two assays. The higher 
resistance of this variant is in agreement with studies previously performed (Azzoni et al, 2008). 
As for pVAX1TSAGFP-Synt it seems to present improved resistance towards the nucleases at 
pH 7 and reduced one at pH 4.7. Further experiments need to be performed in order to assess 
these trends. 
 
4.2. Quantification of number of plasmid copies 
 
The number of pDNA copies inside transfected HeLa and CHO cells was quantified by real-time 
PCR (Table 1). The calibration curve obtained, to allow quantifying the number of copies, 
showed a linear response with a regression coefficient of 0.9972 (appendix 2).  
 
 
Table  1 - Quantification of pDNA molecules per cell by Real-Time PCR 
 
pDNA Molecules.cell-1 Transfected 
cells Plasmids Average Std error 
CHO 
 pVAX1TSAGFP  28608 7996 
 pVAX1TSAGFP-O2  21820 6606 
 pVAX1TSAGFP-Synt  20528 6926 
HeLa 
 pVAX1TSAGFP  8658 1342 
  pVAX1TSAGFP-O2  20684 2629 
  pVAX1TSAGFP-Synt  17526 2472 
 
 
According to Azzoni and coworkers (2007), pVAX1GFP-Synt presented a higher number of 
copies per HeLa cell than the pVAX1GFP-BGH, the starting plasmid. This is due to nuclease 
resistance of pVAX1GFP-Synt which is more resistant to intracellular degradation than the 
pVAX1GFP-BGH plasmid.  
Experimental results show that for HeLa cells the number of pDNA copies was higher for 
pVAX1TSAGFP-O2 and pVAX1TSAGFP-Synt plasmids, when compared with pVAX1TSAGFP. 
This is possibly due to the modifications imposed in the plasmids conferring more resistance to 
nucleases in accordance with previous works (Azzoni, et al., 2007). However, when HeLa cells 
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are compared with CHO cells, there is a shift in the results obtained in comparison with those 
published by (Azzoni, et al., 2007), however, the number of copies of all plasmids is roughly the 
same. Since the plasmids pVAX1TSAGFP-O2 and pVAX1TSAGFP-Synt differ from 
pVAX1TSAGFP in the origin and poly A signal respectively, the role and function of those 
sequences at the post-transcriptional level should be responsible for the differences in 
transgenic expression (Azzoni, et al., 2007).  
Although the fate of the pDNA molecules that reach the cell nucleus is not yet completely 
understood, it is clear that successful expression requires plasmids to remain intact in the cell 
nucleus for a prolonged period of time (Gasiorowki et al., 2005). In accordance with results 
obtained by Azzoni and coworkers (2007), the number of copies of pDNA per cell in CHO and 
HeLa cells is higher when these cell lines are transfected with plasmids with increased nuclease 
resistance. This is reinforced with the results obtained in this particular study.  
 
4.3. Determination of mRNA 
 
Since the results obtained by flow cytometry and real time-PCR were inconclusive,the effect of 
modifications in poly A and origin of replication (pVAX1TSAGFP-Synt and pVAX1TSAGFP-O2 
respectively) were also assessed through a qualitative estimation the mRNA transcripts. For this 
purpose, a calibration curve correlating the amount of RNA with the amount of GFP in 
transfected cells was produce using hystorical transfection data from the laboratory (appendix1). 
By multiplying the transfection percentage and the mean cell fluorescence intensity, we obtain a 
measure of the amount of fluorescent fusion protein expressed. Then, this figure is used with the 
referred calibration curve, and the amount of RNA is thus estimated. In Table2 we can see 
qualitatively estimation of the percentage of mRNA by observing the expression of the reporter 
gene GFP, which shows that there is a perfect correlation between the quantity of protein and 
the quantity of mRNA transcripts. 
 
Table  2 - Quantification of RNA 
 
    
% T MI GFP mRNA pDNA 
CHO pVAX1TSAGFP 12.76 179.91 2296 20880 28608 
 pVAX1TSAGFP-Synt 10.26 111.92 1148 10443 21820 
  pVAX1TSAGFP-O2 14.68 125.69 1845 16779 20528 
HeLa pVAX1TSAGFP 23.63 32.31 763 6942 8658 
 pVAX1TSAGFP-Synt 16.75 15.05 252 2292 20684 
  pVAX1TSAGFP-O2 19.04 15.87 302 2749 17526 
%T corresponds to transfection percentage; MI corresponds to Mean intensity; GFP corresponds to the 
product between %T and MI. 
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Observation of the latter results show that even though the transfection percentage was low, the 
number of mRNA transcripts were high as expected; normally the number of mRNA copies is 
higher than the number of the plasmids it-self. A similar pattern was obtained with CHO and 
HeLa cells, namely higher values for plasmid pVAX1TSAGFP when compared to the other 
plasmid constructions. Both pVAX1TSAGFP-Synt and pVAX1TSAGFP-O2 have similar results. 
Once again, no conclusive results were obtained. More assays are necessary for conclude that 
there are significant difference between the plasmids constructions. 
The results strongly suggest that modifications of the polyadenylation signal and of origin of 
replication are important not only for pDNA resistance, but also for mRNA stability, although no 
definitive conclusions can be taken.   
 
4.4. In vivo assays 
 
In order to assess the effect of the modifications in vivo, 5-8 weeks-old Balb/C mice were 
immunized intramuscularly with two 50 ug doses of each plasmid (pVAX1TSAGFP, 
pVAx1TSAGFP-O2, and pVAX1TSAGFP-Synt) in PBS. Each study group (pVAX1TSAGFP, 
pVAx1TSAGFP-O2, and pVAX1TSAGFP-Synt) had five mice. A control group was also included 
in the experiment where mice were injected with PBS alone. After a period of 12, 20, 35 and 53 
days post-immunization, blood samples were collected and serum was pooled for each group. 
Subsequently, the production of IgG antibodies in serum samples of immunized and non-
immunized was evaluated by ELISA. This test was performed to determine the humoral 
response, hence, the anti-trypanosome IgG antibodies production. In order to determine the best 
conditions to perform ELISA test different settings were evaluated (Figure 8). 
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Figure 8 - Test of different types of extracts to coat ELISA plates.Total protein extract from Trypanossoma 
brucei brucei in carbonate buffer pH 8.5 non diluted (T. brucei 16µg/µl) and diluted (T .brucei 1.6µg/µl). 
Recombinant protein TSA (200ng/well and 100 ng/well). 
 
 
The results show that the use of T. brucei total protein extracts (1.6 µg/µl) reveal similar 
antibodies titres as the ones obtained by the use of 200 ng/well of recombinant protein TSA.  
In accordance with the results obtained, Elisa plates were coated with T. brucei total protein 
extracts (1.6 µg/µl) as it is easier to obtain the extract. 
Figure 9 shows optical density (OD) along time at different dilutions obtained in the course of 
DNA immunization with the plasmids mentioned earlier. The results suggest that IgG antibody 
increases in function of the post-immunization days. The maximum OD was achieved in mice 
with 21 and 42 days post-immunization when compared with control group. Additionally, IgG 
antibody production in immunized and non-immunized mice was performed for IgG isotype.  
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Figure 9- IgG humoral immune response elicited by DNA vaccination. A - Groups of mice immunized with 
50 µg of plasmid or 100 µl of phosphate buffer saline alone (control group) by intramuscular way. Humoral 
immune response was measured 12, 20, 35 and 53 days after immunization. B- Same groups of 
immunized mice discounting the optical density obtained for non-immunized group (PBS). These results 
are represented from pool of serum from five animals per group. 
 
Several works have reported that injection of pDNA encoding antigens of different 
microorganisms resulted in the expression of the corresponding proteins in vivo. In the animal 
models intramuscular or intradermal pDNA injection results in antigen synthesis which once 
synthesised within the transfected eukaryotic cells undergo, trafficking, modification, and antigen 
presentation to the immune system (Silva et al., 2008). 
In accordance with Figure 9, a tendency of immunization can be observed which corresponds to 
an adaptation period (approximately one week). It is expected to have lower titre of antibodies in 
circulation with levels comparable to those obtained for Horse Radish Peroxidase. After this 
period B-cells are activated and the antigen becomes more immunogenic. An increase in optical 
density is observed. Then, a decrease in titre is observed due to the half-time life period of the 
antibodies. This first response had a period of roughly two weeks.  
A faster response was obtained when a second dose of pDNA was administrated, due to the 
presence of memory cells. Similar levels of optical densities were reached after approximately 
one week.   
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In order for it to be considered as humoral response, the titre values should be higher than the 
control, in this case PBS. This situation is only observed in mice immunized with 
pVAX1TSAGFP (Figure 9 A). For the other plasmid humoral response can not be assumed as 
the titres shows inferior values when compared with the control (Figure 9 A and B). This is 
maybe due to the inespecificity of the cellular defense response mechanism.  
More precisely, in the set of experiments, in which mice received only DNA, an apparently higher 
titre was detected in serum samples taken from immunized mice at 21 and 42 days after 
immunization, when compared to the levels determined in the control group (injected with PBS, 
a standard placebo). 
Considering the results obtained for the different plasmids, more assays are necessary to 
optimize this technique in order to have more security in the conclusions to be taken.  
The overall efficacy of plasmid DNA immunization depends on increasing the plasmids 
imunogenicity while, at the same time, correcting for factors involved in the specific activation of 
immune effector cells.  
 
4.5. Challenge assays 
 
The DNA vaccines prototypes (pVAX1TSAGFP-Synt, pVAX1TSAGFP and pVAX1TSAGFP-O2) 
constructed were used to immunize outbred Balb/C mice as described in the methodology 
section. The efficacy of the vaccine prototypes constructed was tested by challenging mice with 
Trypanosoma brucei brucei in order to confirm if there is a relationship between immune 
response and the improved nuclease resistance already described in vitro (Ribeiro et al., 2004; 
Azzoni et al., 2007; Azzoni et al., 2008). The analysis of challenge assay consists on the 
comparison of the survival rate from immunized mice with the three plasmids pVAX1TSAGFP-
Synt, pVAX1TSAGFP and pVAX1TSAGFP-O2 along the infection; the immunized groups were 
compared with non-immunized PBS control group. This allows us to check the normal 
progression of the disease with the putative effect of the candidate vaccines. On Figure 10, the 
parasites are clearly seen in a blood sample taken 28 days after infection. 
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Figure 10 - Blood sample of Balb/C with Trypanosoma brucei brucei 28 days after infection. The staining 
was performed by the method Giemsa and observed with an magnification of 600x. 
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Figure 11 - Survival percentage of outbred Balb/C mice after infection with Trypanosoma brucei brucei . 
 
In the beginning of the infection course, it is observed that the control group show a higher 
survival rate when compared with the group immunized with pVAX1TSAGFP-O2. However, 
when compared with the other groups it is observed that pVAX1TSAGFP shows an equal rate 
and pVAX1TSAGFP-Synt roughly higher one (Figure11). 
Nonetheless, the immunized groups along the infection didn’t show to have a strong resistance 
to the infection, when compared to the non-immunized. This can be explained with the fact that 
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the pDNA were not strong enough to cause a protective effect on immunized mice. As far as the 
infection is concerned, it seems to be an inversion of the situation, as immunized mice with 
pVAX1TSAGFP-Synt and with pVAX1TSAGFP resist after the death of all control mice. Besides 
these results have shown a positive relationship between the improved nuclease resistances of 
this pDNA vectors, more work should be done in order to increase plasmids imunogenicity. More 
assays are needed to optimize and to strengthen data so that it can be concluded with 
confidence that the DNA vaccine prototypes are ready to give the protection effect necessary to 
resist to Trypanosoma brucei brucei parasites. 
 
 
5. Conclusion and further work 
 
The improved plasmid constructs based on TSA expression, developed in this study, have 
shown to be resistant to nucleases, which means that they are strong enough to overcome 
obstacles that the target organ/tissue may impose along trafficking and nuclear delivery. The 
modifications done in polyadenylation signal and also in the origin of replication sequences are 
crucial for their resistance and are maintained even when a new relevant gene, TSA, is cloned in 
the plasmid. There was an apparent relationship between in vitro resistance and the protective 
effect for plasmid pVAX1TSAGFP-Synt. 
Nonetheless, more assays should be done in order to confirm differences between the plasmids 
and also to corroborate them with the immune response.  
According to the results obtained, it is necessary to develop a new vaccination strategy which 
could include the optimization of protocols, such as: i) increasing the amount of plasmid injected, 
ii) increasing the number of immunization boost, iii) creation of multivalent vaccine and iv) the 
use of adjuvants. The study of cellular response would be of great importance to understand the 
immune response to these vaccines.  
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7. Appendix 
 
Appendix 1 
 
Calibration curve RNA/GFP 
 
Regression:
y = 9.0946x
R2 = 0.9919
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Appendix 2 
 
Calibration curve real-time-PCR 
y = -3.7335x + 24.7
R2 = 0.9972
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* NM- number of molecules 
